½ÃÀ庸°í¼­
»óǰÄÚµå
1654193

°æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ÀÌ½Ä ¼ø¼­º°, Àç·áº°, ¸ÞÄ¿´ÏÁòº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)

Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Implantation Procedure (Transfemoral, Transapical), By Material, By Mechanism, By End Use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â¿¡ °ÉÃÄ CAGR 6.6%·Î È®´ëµÇ¸ç 2030³â¿¡´Â 102¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

³ëÀÎ Àα¸ Áõ°¡¿Í ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ(AS)°ú °°Àº À§Çè ¿äÀÎÀÇ ¸¸¿¬Àº °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú(TAVR) ¼ö¿ä¸¦ °è¼Ó °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ½ÉÀå ¿¬¸Í 2022¿¡ µû¸£¸é, ·ù¸¶Æ¼½º¼º ½ÉÀå ÁúȯÀº ¼¼°è¿¡¼­ 3,900¸¸ ¸íÀÌ ¾Î°í ÀÖ´Ù°í ±â·ÏµÇ¾ú½À´Ï´Ù. À̰ÍÀº ·ù¸¶Æ¼½º ¿­ÀÌ ½ÉÀå ÆÇ¸·¿¡ ¿µ±¸ÀûÀÎ ¼Õ»óÀ» ÁÖ´Â Áúº´ÀÔ´Ï´Ù. 2022³â 1¿ù¿¡ ¹ßÇ¥µÈ 'Uncovering the treatable burden of severe AS in the UK'¶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ µû¸£¸é, 2019³â ¿µ±¹¿¡¼­ ÁßÁõ ASÀÇ À¯º´·üÀº 1.48%·Î 55¼¼ ÀÌ»óÀÇ ³²³à 29¸¸ 1,448¸íÀÌ ¾Î°í ÀÖ¾ú½À´Ï´Ù.

ÀÌ·¯ÇÑ ¼öÄ¡ÀÇ °á°ú·Î TAVR ¼ö¿ä´Â ÇâÈÄ ¼ö³â°£ Áõ°¡ÇÏ°í ½ÃÀå È®´ë¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ½ÉÀå ÆÇ¸·ÁõÀÇ À¯º´·ü »ó½Â°ú ½Å±ÔÇϰí Á¤±³ÇÑ TAVR ±â±â¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. AS ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù, ¿¹³ª ¹ëºê ±â¼úÀº Áß±¹ Peijia Medical Limited¿Í µ¶Á¡Àû ±â¼ú ¶óÀ̼±½º °è¾àÀ» ü°áÇϰí Àü·«Àû Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. ÀÌ °è¾à Á¶°Ç¿¡ µû¸£¸é Peijia´Â ½É°¢ÇÑ ÁõÈļº ´ëµ¿¸Æ ÆÇ¸· Æó¼â ºÎÀüÁõ(AR) ¹× ½ÉÇÑ ÁõÈļº AS ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇØ ¿¹³ª ¹ëºêÀÇ Trilogy TAVR ½Ã½ºÅÛÀ» Á¦Á¶ ¹× ÆÇ¸ÅÇÏ´Â Áß±¹¿¡¼­ µ¶Á¡Àû ±Ç¸®¸¦ ºÎ¿©Çß½À´Ï´Ù.

°æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ÀÌ½Ä ÀýÂ÷º°·Î °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼úÀÌ 2024³â ¸ÅÃâ¿¡¼­ 51.5%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼úÀº °æ°ß°©°ñÆÇ ġȯ¼ú, °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ¹× ±âŸ ¹ëºê ġȯ¼ú°ú ºñ±³ÇÏ¿© °¡Àå ¸¹ÀÌ ¼öÇàµË´Ï´Ù. °Ô´Ù°¡, ´õ ÀÛÀº ÇÁ·ÎÆÄÀÏÀÇ ÀåÄ¡¿Í È®Àå °¡´ÉÇÑ ¿ÜÀåÀº °æ´ë Çã¹÷Áö ±â¼ú·Î ¼º°øÀûÀ¸·Î Àü´ÞÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
  • Àç·áº°·Î ´ÏƼ³î ºÎ¹®Àº 2024³â 35.3%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ´ÏƼ³îÀº °­·ÂÇÑ »ý¹°ÇÐÀû Ư¼º°ú ź¼º Ư¼ºÀ» °¡Áö¸ç °æÄ«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÇ ÀÌ»óÀûÀÎ Àç·áÀÔ´Ï´Ù.
  • ¸ÞÄ¿´ÏÁòº°·Î dz¼± È®ÀåÇü ¹ëºê ºÎ¹®Àº 2024³â 55.7%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. dz¼± È®ÀåÇü ½ÉÀå ÆÇ¸·Àº 2÷ÆÇ¿¡ »ç¿ëµÇ´Â °æ¿ì ³ôÀº ±â¿ï±â¸¦ ¾òÀ» ¼ö ÀÖ°í, ȯÇü ÆÄ¿­ÀÇ ºñÀ²ÀÌ Áõ°¡Çϱ⠶§¹®¿¡ °ßÁ¶ÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î º´¿ø ºÎ¹®Àº 2024³â 88.0%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À̰ÍÀº ÁַΠȯÀÚ ¼ö Áõ°¡, º´¿ø¿¡¼­ ½Ç½ÃµÇ´Â TAVR ÀýÂ÷ Áõ°¡, À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À ¶§¹®ÀÔ´Ï´Ù.
  • 2024³â¿¡´Â ºÏ¹Ì°¡ ¾à 38.7%ÀÇ Á¡À¯À²·Î ¼¼°è ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀº ½ÉÀå ÆÇ¸·ÁõÀÇ À¯º´·ü Áõ°¡, ½ÉÀå ÆÇ¸· ġȯ¼ú Áõ°¡, Á¦Ç° Áøº¸, È®¸³µÈ °Ç°­ °ü¸® ÀÎÇÁ¶óÀÔ´Ï´Ù.
  • 2022³â ¹Ì±¹ ½ÉÀ庴ÇÐȸ(American College of Cardiology Foundation)¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ASÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç 150¸¸¸í ÀÌ»óÀÌ AS·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå °ßÀÎ ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå : ÀÌ½Ä ÀýÂ÷ÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ ÀÌ½Ä ÀýÂ÷ÀÇ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸Æ ¹ëºê ġȯ¼ú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÀÌ½Ä ¼ø¼­º°(2018-2030³â)
  • ´ëÅð °æÇÇ
  • ´ëÅð°ñ
  • ´ëµ¿¸Æ

Á¦5Àå °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå : Àç·áÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ Àç·á º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸Æ ¹ëºê ġȯ¼ú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Àç·áº°(2018-2030³â)
  • ´ÏƼ³î
  • ÄÚ¹ßÆ® Å©·Ò
  • ½ºÅ×Àη¹½º ½ºÆ¿
  • ±âŸ

Á¦6Àå °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå : ¸ÞÄ¿´ÏÁòÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ ¸ÞÄ¿´ÏÁò º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸Æ ¹ëºê ġȯ¼ú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¸ÞÄ¿´ÏÁòº°(2018-2030³â)
  • dz¼± È®Àå °¡´É
  • ÀÚ±â È®Àå °¡´É

Á¦7Àå °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå : ÃÖÁ¾ ¿ëµµÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ °æÄ«Å×ÅÍ ´ëµ¿¸Æ ¹ëºê ġȯ¼ú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦8Àå °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå : Áö¿ªÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â¡¤2030³â)
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷/°æÀïÀÇ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷½ÃÀå Æ÷Áö¼Å´× ºÐ¼®(2024³â)
  • ÁÖ¿ä ÀÎÁõ Á¦°ø¾÷ü/°èȹ ¼ÒÀ¯ÀÚ ¸ñ·Ï
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
    • Medtronic plc
    • Abbott Laboratories, Inc.
    • Boston Scientific Corporation
    • Meril Life Sciences Pvt. Ltd.
    • Edwards Lifesciences Corp.
    • St. Jude Medical, Inc.
    • JenaValve Technology, Inc.
    • Bracco SpA
    • Transcatheter Technologies GmbH
KTH 25.03.04

Transcatheter Aortic Valve Replacement Market Growth & Trends:

The global transcatheter aortic valve replacement market size is expected to reach USD 10.2 billion by 2030, expanding at a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising geriatric population and the prevalence of risk factors like aortic valve stenosis (AS) and other diseases continue to drive the demand for transcatheter aortic valve replacement (TAVR) procedures. According to the World Heart Federation 2022, rheumatic heart disease affected 39 million individuals globally. It is a disorder in which rheumatic fever permanently damages the heart valves. According to a January 2022 published study titled "Uncovering the treatable burden of severe AS in the U.K.", the prevalence of severe AS in the U.K. in 2019 was 1.48%, affecting 291,448 men and women aged 55 or above.

As a result of these figures, the demand for TAVR is expected to rise in the coming years, contributing to the market's expansion. Furthermore, the rising prevalence of heart valve disease and increased regulatory approvals for novel and sophisticated TAVR devices drive market growth. The rising prevalence of AS disease is a main factor driving the market's expansion. For instance, in January 2022, JenaValve Technology, Inc. formed a strategic alliance with an exclusive technology licensing agreement with Peijia Medical Limited in China. According to the terms of the deal, Peijia has been granted exclusive rights in China to produce and distribute JenaValve's Trilogy TAVR systems for treating patients with significant symptomatic aortic regurgitation (AR) and severe symptomatic AS.

Transcatheter Aortic Valve Replacement Market Report Highlights:

  • Based on the implantation procedure, the transfemoral segment held the largest market share of 51.5% in terms of revenue in 2024. Transfemoral is the most performed procedure in comparison with transapical, transaortic, and other implantation procedures. Moreover, smaller profile devices and expandable sheaths can be successfully delivered via the transfemoral technique.
  • Based on material, the nitinol segment held the largest market share of 35.3% in 2024. Nitinol has strong biological and elastic properties, making it an ideal material for transcatheter heart valves.
  • Based on the mechanism, the balloon-expandable valve segment held the largest market share of 55.7% in 2024. It promises robust growth due to its higher gradients when deployed in bicuspid anatomies and due to an increase in the rate of annular ruptures.
  • Based on end-use, the hospital segment accounted for the largest market share of 88.0% in 2024. This is mainly due to the increasing patient base, increased TAVR procedures undertaken in hospitals, and favorable reimbursement scenarios.
  • In 2024, North America dominated the global market with a share of around 38.7%. The primary drivers for market expansion are the rising prevalence of heart valve illness, the increased number of heart valve replacement procedures, product advancements, and the well-established healthcare infrastructure.
  • According to the 2022 American College of Cardiology Foundation, the prevalence of AS is increasing in the U.S., with more than 1.5 million individuals in the U.S. suffering from AS.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Implantation Procedure Segment
    • 1.2.2. Material Segment
    • 1.2.3. Mechanism Segment
    • 1.2.4. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Transcatheter Aortic Valve Replacement Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence of aortic stenosis
      • 3.2.1.2. Rising demand for the minimally invasive procedure
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High procedure costs
      • 3.2.2.2. Regulatory and reimbursement challenges
  • 3.3. Transcatheter Aortic Valve Replacement Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Transcatheter Aortic Valve Replacement Market: Implantation Procedure Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Transcatheter Aortic Valve Replacement Market Implantation Procedure Movement Analysis
  • 4.3. Global Transcatheter Aortic Valve Replacement Market Size & Trend Analysis, by Implantation Procedure, 2018 - 2030 (USD Billion)
  • 4.4. Transfemoral
    • 4.4.1. Transfemoral market estimates and forecasts 2018 - 2030 (USD Billion)
  • 4.5. Transapical
    • 4.5.1. Transapical market estimates and forecasts 2018 - 2030 (USD Billion)
  • 4.6. Transaortic
    • 4.6.1. Transaortic market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 5. Transcatheter Aortic Valve Replacement Market: Material Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Transcatheter Aortic Valve Replacement Market Material Movement Analysis
  • 5.3. Global Transcatheter Aortic Valve Replacement Market Size & Trend Analysis, by Material, 2018 - 2030 (USD Billion)
  • 5.4. Nitinol
    • 5.4.1. Nitinol market estimates and forecasts 2018 - 2030 (USD Billion)
  • 5.5. Cobalt chromium
    • 5.5.1. Cobalt chromium market estimates and forecasts 2018 - 2030 (USD Billion)
  • 5.6. Stainless steel
    • 5.6.1. Stainless steel market estimates and forecasts 2018 - 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 6. Transcatheter Aortic Valve Replacement Market: Mechanism Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Transcatheter Aortic Valve Replacement Market Mechanism Movement Analysis
  • 6.3. Global Transcatheter Aortic Valve Replacement Market Size & Trend Analysis, by Mechanism, 2018 - 2030 (USD Billion)
  • 6.4. Balloon-expandable
    • 6.4.1. Balloon-expandable market estimates and forecasts 2018 - 2030 (USD Billion)
  • 6.5. Self-expandable
    • 6.5.1. Self-expandable market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 7. Transcatheter Aortic Valve Replacement Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Transcatheter Aortic Valve Replacement Market End Use Movement Analysis
  • 7.3. Global Transcatheter Aortic Valve Replacement Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Billion)
  • 7.4. Hospitals
    • 7.4.1. Hospitals market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.5. Ambulatory Surgical Centers
    • 7.5.1. Ambulatory surgical centers market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 8. Transcatheter Aortic Valve Replacement Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Competitive scenario
      • 8.4.1.3. Regulatory framework
      • 8.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory framework
      • 8.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory framework
      • 8.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Competitive scenario
      • 8.5.1.3. Regulatory framework
      • 8.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory framework
      • 8.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory framework
      • 8.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory framework
      • 8.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.6. Denmark
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Denmark market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory framework
      • 8.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory framework
      • 8.5.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Competitive scenario
      • 8.6.1.3. Regulatory framework
      • 8.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory framework
      • 8.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory framework
      • 8.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory framework
      • 8.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory framework
      • 8.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Competitive scenario
      • 8.7.1.3. Regulatory framework
      • 8.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Competitive scenario
      • 8.8.1.3. Regulatory framework
      • 8.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory framework
      • 8.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Billion)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory framework
      • 8.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. List of Key Certification Providers/Scheme Owners
  • 9.5. Company Profiles/Listing
    • 9.5.1. Medtronic plc
      • 9.5.1.1. Company overview
      • 9.5.1.2. Financial performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic initiatives
    • 9.5.2. Abbott Laboratories, Inc.
      • 9.5.2.1. Company overview
      • 9.5.2.2. Financial performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic initiatives
    • 9.5.3. Boston Scientific Corporation
      • 9.5.3.1. Company overview
      • 9.5.3.2. Financial performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic initiatives
    • 9.5.4. Meril Life Sciences Pvt. Ltd.
      • 9.5.4.1. Company overview
      • 9.5.4.2. Financial performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic initiatives
    • 9.5.5. Edwards Lifesciences Corp.
      • 9.5.5.1. Company overview
      • 9.5.5.2. Financial performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic initiatives
    • 9.5.6. St. Jude Medical, Inc.
      • 9.5.6.1. Company overview
      • 9.5.6.2. Financial performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic initiatives
    • 9.5.7. JenaValve Technology, Inc.
      • 9.5.7.1. Company overview
      • 9.5.7.2. Financial performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic initiatives
    • 9.5.8. Bracco SpA
      • 9.5.8.1. Company overview
      • 9.5.8.2. Financial performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic initiatives
    • 9.5.9. Transcatheter Technologies GmbH
      • 9.5.9.1. Company overview
      • 9.5.9.2. Financial performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦